Aktienanalyse zu Boundless Bio, Inc. (BOLD)BOLDBoundless Bio, Inc.

Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that address the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target. It operates in the Healthcare sector.

Boundless Bio Inc (BOLD) appears to be a good buy at the current price of $2.44, especially considering the recent insider buying activity where Kevin Tang purchased shares at $2.50, reflecting confidence in the company's future. The stock has shown a year-to-date change of +100.00%, indicating strong momentum. However, the main risk is the negative earnings trend, with the most recent EPS reported at -1.06, which highlights ongoing financial challenges.

7 analysts cover BOLD: 5 rate it Buy, 2 Hold and 0 Sell. The average price target is 4.00.